Effect of atorvastatin, with or without ezetimibe, on serum lipid profile and ALT in hyperlipidemic patients

Showan D. Husain; Wishyar Abbas Hamad

doi:10.15218/zjms.2011.0003

Authors

Showan D. Husain Department of Clinical Analysis, College of Pharmacy, HMU, Erbil, Iraq
Wishyar Abbas Hamad Diabetic Center, Ministry of Health, Erbil, Iraq

DOI:

https://doi.org/10.15218/zjms.2011.0003

Keywords:

hyperlipidaemia, atherogenic index, atorvastatin, ezetimibe, alanine aminotransferase

Abstract

Background and objectives: Hyperlipidaemia is raised serum levels of one or more of total cholesterol, low-density lipoprotein and triglycerides. Many drugs have been used for the treatment of this disorder. This work compares the effects of atorvastatin with or without ezetimibe on lipid profile, atherogenic index and serum alanine aminotransferase.

Methods: This study covers 90 subjects, 60 untreated hyperlipidemic patients, and 30 healthy subjects. Patients were divided into 2 groups, the first group included 30 patients treated with atorvastatin 20 mg/day alone, the second group included 30 patients treated with a combination of 2 drugs (atorvastatin 10 mg plus ezetimibe 10 mg) taken daily at night. Serum lipid profile, atherogenic index and serum alanine amniotransferase were measured after 12 hours fasting for the patients in 3 intervals: before, and after 8 weeks and 16 weeks of treatment.

Results: After therapy for both groups of patients, as compared to the levels before treatment, has shown that serum total cholesterol, triglycerides, low density lipoprotein cholesterol and very low density lipoprotein cholesterol were significantly reduced while high density lipoprotein cholesterol was significantly increased. Serum alanine aminotransferase increased by both groups of treatment with no significant difference between the two modes of treatment which has the same findings in comparison to the control group.

Conclusion: Combination of atorvastatin 10 mg and ezetimibe 10 mg daily, is more effective than atorvastatin 20 mg taken alone.

Metrics

Metrics Loading ...

References

Grundy SM. Cholesterol and coronary heart disease: A new era. Journal of the American Medical Association 1986; 256(20):2849-2858.

Chin-Dusting JP and Shaw JA. Lipids and atherosclerosis: clinical management of hypercholesterolaemia. Expert Opinion on Pharmacotherapy 2001; 2(3):419-430.

Farnier M and Davignon J. Current and future treatment of hyperlipidemia: the role of statins. American Journal of Cardiology 1998 ;82(4B):3J-10J.

Jochen K, Jean-Paul T and Bozidar V. Text Book of Clinical pharmacology. McGraw-Hill 2000. pp. 700-714.

Katazung B.G. Text Book of Basic and clinical pharmacology. 10th ed. 2007: p. 560-573.

Charles Z, Pugh E and Barnett D. Ezetimibe for the treatment of primary (heterozygous-familial and non-familial) hypercholesterolaemia: NICE technology appraisal guidance. BMJ 2008 ; 94:642-643.

Daniel W.W. Biostatistics: A foundation for analysis in the health science. 3rd ed. Jon Wiley and Sons 1983 . USA.

Thompson GR. A Handbook of Hyperlipidemia. London, England: Current Science 1990 : 177–194

Arad Y, Ramakrishnan R and Ginsberg H. Lovastatin. Therapy reduces low density lipoprotein apo B level in subjects with combined hyperlipidemia by reducing the production of apo B containing lipoproteins: implications for the pathophysiology of apo B production. J Lipid Res 1990 ; 31:567–582.

Nawrocki JW, Weiss SR, Davidson MH Sprecher DL, Schwartz SL . Reduction of LDL cholesterol by 25% to 60% in patients with primary hypercholesterolemia by atorvastatin, a new HMG-CoA reductase inhibitor. Arterioscler Thromb Vasc Biol 1995; 15:678–682.

Marian G, Soledad GV and Vicente L. Effects of Atorvastatin on inflammatory and fibrinolytic parameters in patients with chronic kidney disease. J Am Soc Nephrol 2006 ; 17: S231–S235.

Blum CBB. Comparison of properties of four inhibitors of 3-hydroxy-3-methyglutaryl-coenzyme A reductase. Am J Cmdiol 1994 ; 73, Suppl D, 3-11.

Rizwan S, Clare N, Shahenaz W, Yvonne T, Mary S . Efficacy of ezetimibe and future role in the management of refractory hyperlipidaemia in high-risk patients. Br J Cardiol 2008; 15(4):205-209

Haria M and McTavish D. Pravastatin a reappraisal of its pharmacological properties and therapeutic use in the management of coronary heart disease. Drugs 1997 ; 53,2:299-336.

Bakker-Arkema RG, Davidson MH and Goldstein RJ . Efficacy and safety of a new HMG-CoA reductase inhibitor, atorvastatin, in patients with hypertriglyceridemia. JAMA 1996 ; 275:128–133.

Athyros VG, Giouleme OI, Nikolaidis NL, Vasiliadis TV, Bouloukos VI. Long-term follow up of patients with acute hypertriglyceridemia-induced pancreatitis. J Clin Gastroenterol 2002B; 34:472–477.

Trifiletti A, Lasco R, Scamardi M.A, Pizzoleo A. Gaudio R. Long-Term Hemostatic effects of cholesterol –lowering therapy with atorvastatin. Pathophysiol Haemost Thromb 2003 ; 33:84–87.

Jeevan k.S, Mungli P and Sudashna T. Effect of atorvastatin paraoxonase activity in patients with hyperlipidemia. Asian journal of biochemistry 2008; 1815-1823.

Martin G, Duez H, Blanquart C, Berezowski V, Poulain P, Fruchart JC. Statin-induced inhibition of the Rho-signaling pathway activates PPARalpha and induces HDL apoA-I. J Clin Invest 2001 ; 107:1423-1432.

Bays H and Stein EA. Pharmacotherapy for dyslipidaemia–current therapies and future agents. Expert Opin Pharmacother 2003 ; 4:1901-1938.

Michael B, Clearfield J.A, Jean-Pierre B Hugo R. Sam S . Comparison of the efficacy and safety of rosuvastatin 10 mg and atorvastatin 20 mg in high-risk patients with hypercholesterolemia. J Biochem 2006 ; 7-35.

Kamran A and didar Z . Efficacy of alternative dosing of atorvastatin. Jornals of Chinese clinical medicine 2007 ; 2: 11-17.

Davis HR, Pula KK, Alton KB, Burrirr R.E and Watkins R.W . The synergistic hypocholesterolemic activity of the potent cholesterol absorption inhibitor, ezetimibe, in combination with 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors in dogs. Metabolism 2001; 50: 1234–1241.

Michael P, Sabine F and Caroline S . Treatment with ezetimibe plus low-dose atorvastatin compared with higher-dose atorvastatin alone. J Am coll of cardiol . 2007 ; 1035-1042

Gupta MS, Manish S, Vijay S Yadav RK, Kaushal A . Ezetimibe as an adjunct to atorvastatin in patients of dyslipidemia. Indian heart J 2005; 57:562-564.

Evan S, Steen S, Pedro M, Sager P, Ponsonnet D. Achieving lipoprotein goals in patients at high risk with sever hypercholesterolemia: efficacy and safety of ezetimibe co-administration with atorvastatin. American heart journal 2004; 148(3):447-455

Rizwan S, Clare N, Shahenaz W, Yvonne T, Mary S. Efficacy of ezetimibe and future role in the management of refractory hyperlipidaemia in high-risk patients. Br J Cardiol 2008 ; 15(4):205-209.

Ballantyne C.M, Houri J, Notarbartolo A, Lorenzo M, Leslie J. Effect of ezetimibe coadministered with atorvastatin in 628 patients with primary hypercholesterolemia: A prospective, randomized, double-blind trial. Circulation 2003 ; 107:2409–2415.